Lucid Diagnostics Inc. LUCD
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a GI/hepatology diagnostics company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EsoGuard (LDT, CLIA/CAP lab; EsoGuard 2.0 multiplexed assay) | Barrett's esophagus / esophageal adenocarcinoma precancer detection | — | NA_NON_THERAPEUTIC |
| EsoCheck (FDA 510(k)-cleared, CE marked) | Esophageal surface cell collection | — | NA_NON_THERAPEUTIC |
Recent results and decisions
- Oct 21, 2026n/a Lucid Diagnostics Inc. closed a $15.0 million Series C Convertible Preferred Stock offering on October 21, 2026.
On October 21, 2026, the Company entered into subscription agreements with certain accredited investors, which agreements provided for the sale to the Series C Investors of 15,000 shares of the Company's newly designated Series C Convertible Preferred Stock at a purchase price of $1,000 per share.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other GI/hepatology companies
- PAVmed Inc. PAVM
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.